150 PsA pts assessed preferences in chosing biologics (of most to less preferred): 1 Oral over SC or IV routes 2 Avoiding severe side effects 3 Resume normal activity 4 Avoid infections 5 Improve enthesitis & 6 psoriasis 7 remission 8 Joint pain https://t.co/kE3qtTWBhH https://t.co/KKcsQqEYKf

Awards issued by ACR, EULAR, BSR Reveal Gender Gap in last 2 decades. While # awards increased (including women), absolute %female prize winners remains lower than males (among 41 total awards). ACR: only ~20% recv top gold medal or Master awards https://t.co/lI548NmeW3 https://t.co/AfRwBANLOE

More Bad Safety News for Xeljanz Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in RA are higher than with TNF inhibitors. https://t.co/5FIwRMXdbT https://t.co/8k4NU6Rh6T

CARRA Registry study of Kids who D/C DMARDs or biologics but flared & restarted meds: the recapture rate was 55% overall (47% oligoarthritis, 69% systemic JIA. By 12 mos 67% of children achieved inactive dz - better odds w/ restarting biologics (OR 2.74) https://t.co/Psgtd0O2jO https://t.co/xsecVRJqOL

Prospective study of 189 new non-infectious anterior uveitis pts, found a high prevalence SpA (56%), 93% w/ axial SpA, few (7) w/ peripheral SpA. 74/106 were newly Dx SpA. SpA predictors: psoriasis (OR 12.5), B27+ (OR 6.3),^CRP (OR 4.8) & male (OR 2.1) https://t.co/uTLmJ2QU1A https://t.co/2rejvp3yTa

Study of diet & RA in 100 new RA & 197 controls; fish/seafood consumption assoc w/ less RA risk (OR 0.52; 0.27–0.98); but processed meat intake yielded increased RA risk (OR 3.45; CI 1.78–6.68). No significant association btw RA and red meats or poultry https://t.co/wLpHfA50mY https://t.co/p2EOLBKrwW

JAK Inhibitors in Difficult Still’s Disease A small retrospective study suggests that patients with difficult to treat AOSD or sJIA may respond well to JAKi agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN. https://t.co/cH9wb8bPTX https://t.co/Xm7DUC5okk

Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/kFQVUdalQp https://t.co/UKtFzReIe6

Amgen and ChemoCentryx, (maker of newly approved Avacopan)have entered into a definitive agreement wherein Amgen will acquire ChemoCentryx for ~$3.7 billion ($52 per share). https://t.co/8quO9ET8vH https://t.co/AphPizgKo8

Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/IoWISgL3SY https://t.co/JV1Yv5Pg9d https://t.co/b8UoQ4zMUV https://t.co/VwNgVQ5End

Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunocompromised pts who might benefit from it. Repeat doses (300 mg) every 6 mos! Time to jump on this! https://t.co/IzcAUvKoW8 https://t.co/h5q25yWCHG

Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/kLa61ZS8dt https://t.co/7XhqxcHuCt